Medical Use
Truseltiq is a kinase inhibitor prescribed for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma that involves a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Recommended Dosage: The standard dosage is 125 mg (one 100 mg capsule and one 25 mg capsule) taken orally once daily for 21 consecutive days, followed by a 7-day break, in 28-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs.
Administration Instructions: Take Truseltiq capsules on an empty stomach, at least one hour before or two hours after a meal, at the same time each day. Swallow the capsules whole with a glass of water. Do not crush, chew, or dissolve them.
Missed Dose: If a dose is missed by 4 hours or more, or if vomiting occurs, resume the regular daily dose schedule the next day.
Dosage Adjustments for Renal and Hepatic Impairment:
- -Mild and Moderate Renal Impairment: 100 mg orally once daily for 21 consecutive days, followed by a 7-day break, in 28-day cycles.
- -Mild Hepatic Impairment: 100 mg orally once daily for 21 consecutive days, followed by a 7-day break, in 28-day cycles.
- -Moderate Hepatic Impairment: 75 mg orally once daily for 21 consecutive days, followed by a 7-day break, in 28-day cycles.
Warning & Precautions
Truseltiq 25 mg capsules can cause Retinal Pigment Epithelial Detachment (RPED), potentially leading to blurred vision. Conduct an ophthalmic examination, including Optical Coherence Tomography (OCT), before starting therapy, at 1 month, at 3 months, and then every three months during treatment. Urgently refer patients for ophthalmic evaluation if visual symptoms occur, and follow up every three weeks until resolution or treatment interruption.
Infigratinib may cause hyperphosphatemia, which can lead to soft tissue mineralization, vascular calcification, cutaneous calcinosis, non-uremic calciphylaxis, and myocardial calcification. Monitor for hyperphosphatemia throughout therapy. Initiate phosphate-lowering therapy when serum phosphate levels exceed 5.5 mg/dL. If serum phosphate levels exceed 7.5 mg/dL, withhold Infigratinib and start phosphate-lowering therapy.
Based on animal studies and its mechanism of action, Infigratinib can cause fetal harm if administered to a pregnant woman. Oral administration of Infigratinib to pregnant animals during organogenesis resulted in malformations, fetal growth retardation, and embryo-fetal death at maternal exposures lower than the human exposure at the clinical dose of 125 mg.
Contraception Recommendations:
- -Females of reproductive age should use effective contraception during treatment with Infigratinib and for at least 30 days after the last dose.
- -Males with female partners of reproductive age should use effective contraception during treatment with Infigratinib and for 30 days after the final dose.
Documentation Availability
Documents required to import Truseltiq to India?
Truseltiq can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Truseltiq from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Truseltiq®?
Infigratinib is Generic Name for the trade name drug Truseltiq®.
What is the Manufacturer Name of Truseltiq®?
Truseltiq® is manufactured by BridgeBio Pharma, Inc.
Is Truseltiq® approved by the FDA?
Yes, Truseltiq® is approved by the FDA. Date of first/initial approval: May 28, 2021.
What is the dosage and form of Truseltiq® supplied?
Truseltiq® is supplied as Capsules: 25 mg and 100 mg for oral administration.
What are the most common side effects with Truseltiq®?
The most common side effects with Truseltiq® include: dry eye, nail toxicity, stomatitis, fatigue, alopecia, dry mouth, palmar-plantar erythrodysesthesia syndrome, arthralgia, constipation, abdominal pain, eyelash changes, dysgeusia, diarrhea, decreased appetite, dry skin, vision blurred and vomiting.
How much does Truseltiq® cost in India?
The cost of Truseltiq in India can vary. It can be procured authentically by ordering it at https://rx4u.in/
What are the storage conditions of Truseltiq®?
Store Truseltiq at temperature 20 to 25°C (68 to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).
Is it safe to buy Truseltiq® online from India?
Yes, You can buy Truseltiq in India at the best price from the Rx4u team.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
